A young girl died after receiving an experimental gene-editing treatment in a clinical trial in Shanghai, Science reported, raising questions about regulatory oversight and transparency as China expands its biotechnology ambitions.
The case has drawn criticism over how the trial was supervised and disclosed.
China Gene-Editing Trial Death Draws Fire
2026-07-24 03:54:15
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
印孚瑟斯任命资深高管应对AI冲击
